VNN1 and sarcoma: As a surrogate mouse model of complex sarcomas, we implanted the Vnn1negative MCA 205 (MCA) sarcoma cell line in immunocompetent mice to test whether systemic administration of Pant would compensate for the lack of Vnn1 in the tumor mass.